Active	Status	Sponsor type	Region	Phase	Filter
6 Active 4 Inactive 10 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

6 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Herfarth, Hans H
NCT04763564: Efficacy of Liraglutide Therapy in Patients With IPAA	Terminated	2	8	US	Liraglutide Pen Injector, Victoza, Placebo Pen Injector, Saline	University of North Carolina, Chapel Hill, Novo Nordisk A/S	Pouchitis, Irritable Pouch Syndrome	10/23	10/23
PROF, NCT05938465: Study of EXE-346 Live Biotherapeutic to Reduce High Bowel Movement Frequency in Subjects with an IPAA	Recruiting	1/2	50	US	EXE-346, Placebo	Exegi Pharma, LLC, The Emmes Company, LLC	Ileal Pouch	05/26	06/26
TOUR, NCT03772145: Tofacitinib Response in Ulcerative Colitis - a Real World Prospective Multi-center Study	Terminated	N/A	103	US		University of North Carolina, Chapel Hill, Pfizer	Ulcerative Colitis	01/23	01/24
NCT06696014: Mirikizumab Real World Protocol	Not yet recruiting	N/A	100	US		University of North Carolina, Chapel Hill, Eli Lilly and Company	Ulcerative Colitis	01/30	01/30
NCT04940611: A Study of Surgical Interventions in Fistulizing Conditions	Active, not recruiting	N/A	750	Europe, Canada, US, RoW		Takeda	Crohns Disease, Fistula, Rectovaginal Fistula, Complex Perianal Fistula, Complex Cryptoglandular Fistula	05/26	05/26
Sandridge, Mikki
NCT06312683: Rifaximin for the Secondary Prevention of Recurrent Pouchitis	Recruiting	4	16	US	Rifaximin 550 MG Oral Tablet [XIFAXAN], Xifaxan	University of North Carolina, Chapel Hill, Bausch Health Americas, Inc.	Pouchitis	07/26	07/26